Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.
- After a long downward spiral, Genticel has become part of Genkyotex, one of the companies battling for a piece of the NASH market
- Takeda has doubled down on Arix with a partnership following its investment in the fund’s IPO
- Swiss biotech Addex added 3M CHF to its cash pile to extend its runway through 2018
- Sanofi Pasteur and Medimmune are collaborating on mAbs to fight RSV-related illnesses
- Asit Biotech has reported positive results from a Phase III trial for a pollen allergy cure
- TopiVert has begun a Phase I study for its ulcerative colitis treatment
- Merck KGaA has bagged a priority review for its checkpoint inhibitor, avelumab
- Sanofi is partnering to launch virtual trials with Science37, an LA-based company
- Guselkumab from Morphosys, in collaboration with Janssen, met all of its primary endpoints in Phase III for plaque psoriasis
- The Chairman of Novartis, Jörg Reinhardt, took a step back from the company’s efforts to make a glucose-sensing smart lens
- There’s a new Research Institute of Molecular Pathology at the Vienna Biocenter, following a €52M investment from Boehringer Ingelheim
Images from LadyWriter55, Jiri Foltyn, Sidarta, Sladic / shutterstock.com
Let's Continue The Conversation
Feel free to send us comments about this article to firstname.lastname@example.org and/or comment on that article on social media.